JPWO2021133752A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021133752A5 JPWO2021133752A5 JP2022538813A JP2022538813A JPWO2021133752A5 JP WO2021133752 A5 JPWO2021133752 A5 JP WO2021133752A5 JP 2022538813 A JP2022538813 A JP 2022538813A JP 2022538813 A JP2022538813 A JP 2022538813A JP WO2021133752 A5 JPWO2021133752 A5 JP WO2021133752A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- methyl
- oxo
- carbonitrile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201911053558 | 2019-12-23 | ||
| IN201911053558 | 2019-12-23 | ||
| PCT/US2020/066510 WO2021133752A1 (en) | 2019-12-23 | 2020-12-22 | Substituted heteroaryl compounds useful as t cell activators |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023508054A JP2023508054A (ja) | 2023-02-28 |
| JP2023508054A5 JP2023508054A5 (https=) | 2024-01-04 |
| JPWO2021133752A5 true JPWO2021133752A5 (https=) | 2024-01-04 |
| JP7677976B2 JP7677976B2 (ja) | 2025-05-15 |
Family
ID=74195155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022538813A Active JP7677976B2 (ja) | 2019-12-23 | 2020-12-22 | Ｔ細胞アクティベーターとして有用な置換ヘテロアリール化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230086933A1 (https=) |
| EP (1) | EP4081524B1 (https=) |
| JP (1) | JP7677976B2 (https=) |
| KR (1) | KR20220119458A (https=) |
| CN (1) | CN114846015B (https=) |
| AU (1) | AU2020412472A1 (https=) |
| BR (1) | BR112022012204A2 (https=) |
| CA (1) | CA3163003A1 (https=) |
| ES (1) | ES3013568T3 (https=) |
| IL (1) | IL294273A (https=) |
| MX (1) | MX2022007372A (https=) |
| WO (1) | WO2021133752A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022009631A2 (pt) * | 2019-12-19 | 2022-08-09 | Bristol Myers Squibb Co | Combinações de inibidores de dgk e antagonistas do ponto de checagem |
| LT4081305T (lt) | 2019-12-24 | 2024-11-25 | Carna Biosciences, Inc. | Diacilglicerolio kinazę moduliuojantys junginiai |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| TW202315620A (zh) * | 2021-08-03 | 2023-04-16 | 英屬開曼群島商百濟神州有限公司 | 吡唑并吡啶酮化合物 |
| WO2023122777A1 (en) * | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
| WO2023122772A1 (en) * | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
| CN118451073A (zh) * | 2021-12-29 | 2024-08-06 | 百济神州有限公司 | 杂环化合物 |
| EP4472963A1 (en) * | 2022-02-01 | 2024-12-11 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
| WO2023165525A1 (en) * | 2022-03-01 | 2023-09-07 | Insilico Medicine Ip Limited | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof |
| KR20240156394A (ko) | 2022-03-01 | 2024-10-29 | 인실리코 메디신 아이피 리미티드 | 디아실글리세롤 키나아제 (dgk) 알파 억제제 및 이의 용도 |
| JP2025510945A (ja) * | 2022-03-31 | 2025-04-15 | インベンティスバイオ カンパニー リミテッド | キナーゼ阻害剤、その製造方法および用途 |
| WO2023184327A1 (en) * | 2022-03-31 | 2023-10-05 | InventisBio Co., Ltd. | Kinase inhibitors, preparation methods and uses thereof |
| US12600723B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| US12600722B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| KR20250046310A (ko) * | 2022-08-09 | 2025-04-02 | 브리스톨-마이어스 스큅 컴퍼니 | T 세포 활성화제로서 유용한 3급 아민 치환된 비시클릭 화합물 |
| CN120615095A (zh) * | 2023-02-02 | 2025-09-09 | 百济神州(苏州)生物科技有限公司 | 作为二酰甘油激酶抑制剂的稠合杂环化合物 |
| JP2026504408A (ja) * | 2023-02-02 | 2026-02-05 | ビーワン メディシンズ ワン ゲーエムベーハー | ヘテロ環式化合物 |
| AR131770A1 (es) * | 2023-02-02 | 2025-04-30 | Beigene Ltd | Compuestos heterocíclicos |
| AR131786A1 (es) | 2023-02-06 | 2025-04-30 | Bayer Ag | Combinación de anticuerpos ccr8 con inhibidores de dgk |
| WO2025030002A2 (en) * | 2023-08-02 | 2025-02-06 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
| WO2025051110A1 (en) * | 2023-09-04 | 2025-03-13 | Insilico Medicine Ip Limited | Combinations treatments of diacylglycerol kinase (dgk) alpha inhibitors and other therapies |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2544939B2 (ja) * | 1987-09-01 | 1996-10-16 | 大塚製薬株式会社 | ベンゾヘテロ環誘導体 |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| AU2006230099B2 (en) | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| CA2634198C (en) | 2005-12-20 | 2014-06-03 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| ES2444574T3 (es) | 2006-09-19 | 2014-02-25 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| ES2776406T3 (es) | 2007-07-12 | 2020-07-30 | Gitr Inc | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| JP5583592B2 (ja) | 2007-11-30 | 2014-09-03 | ニューリンク ジェネティクス コーポレイション | Ｉｄｏ阻害剤 |
| US20110176972A1 (en) | 2008-05-29 | 2011-07-21 | Saint-Gobain Centre De Recherches et D'Etudes Eur | Cellular structure containing aluminium titanate |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| EP2473531A4 (en) | 2009-09-03 | 2013-05-01 | Merck Sharp & Dohme | Anti-gitr antibodies |
| US8722720B2 (en) | 2009-10-28 | 2014-05-13 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
| PH12012500881A1 (en) | 2009-12-10 | 2017-07-26 | Hoffmann La Roche | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| JP5998060B2 (ja) | 2010-03-04 | 2016-09-28 | マクロジェニクス，インコーポレーテッド | Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用 |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| CA2789076C (en) | 2010-03-05 | 2017-11-21 | F. Hoffmann-La Roche Ag | Antibodies against human colony stimulating factor-1 receptor and uses thereof |
| MX378336B (es) | 2010-05-04 | 2025-03-10 | Five Prime Therapeutics Inc | Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r). |
| PT2614082T (pt) | 2010-09-09 | 2018-12-03 | Pfizer | Moléculas de ligação a 4-1bb |
| NO2694640T3 (https=) | 2011-04-15 | 2018-03-17 | ||
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| BR112014012624A2 (pt) | 2011-12-15 | 2018-10-09 | F Hoffmann-La Roche Ag | anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo |
| RU2014136332A (ru) | 2012-02-06 | 2016-03-27 | Дженентек, Инк. | Композиции и способы применения ингибиторов csf1r |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| EP2847220A1 (en) | 2012-05-11 | 2015-03-18 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| JP6464139B2 (ja) * | 2013-03-14 | 2019-02-06 | コンバージーン・リミテッド・ライアビリティ・カンパニーＣｏｎｖｅｒｇｅｎｅ Ｌｌｃ | ブロモドメイン含有タンパク質の阻害のための方法および組成物 |
| CN112654621B (zh) * | 2018-06-27 | 2024-05-14 | 百时美施贵宝公司 | 可作为t细胞活化剂的经取代萘啶酮化合物 |
| PT3814347T (pt) * | 2018-06-27 | 2023-07-18 | Bristol Myers Squibb Co | Compostos de naftiridinona úteis como ativadores de células t |
| JPWO2020071550A1 (ja) * | 2018-10-04 | 2021-09-24 | 京都薬品工業株式会社 | Ｃｄｋ８阻害剤およびその用途 |
-
2020
- 2020-12-22 IL IL294273A patent/IL294273A/en unknown
- 2020-12-22 CN CN202080089546.2A patent/CN114846015B/zh active Active
- 2020-12-22 US US17/785,585 patent/US20230086933A1/en active Pending
- 2020-12-22 WO PCT/US2020/066510 patent/WO2021133752A1/en not_active Ceased
- 2020-12-22 BR BR112022012204A patent/BR112022012204A2/pt not_active IP Right Cessation
- 2020-12-22 AU AU2020412472A patent/AU2020412472A1/en not_active Abandoned
- 2020-12-22 EP EP20845305.0A patent/EP4081524B1/en active Active
- 2020-12-22 MX MX2022007372A patent/MX2022007372A/es unknown
- 2020-12-22 KR KR1020227025312A patent/KR20220119458A/ko active Pending
- 2020-12-22 JP JP2022538813A patent/JP7677976B2/ja active Active
- 2020-12-22 CA CA3163003A patent/CA3163003A1/en active Pending
- 2020-12-22 ES ES20845305T patent/ES3013568T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021133752A5 (https=) | ||
| CN101128461B (zh) | 作为VEGF-R2抑制剂的咪唑并[1,2-a]吡啶化合物 | |
| CN114728912A (zh) | Mta-协同prmt5抑制剂 | |
| US7776857B2 (en) | Aurora kinase modulators and method of use | |
| CN101641093B (zh) | 作为激酶抑制剂的咪唑并三嗪和咪唑并嘧啶 | |
| ES2274712B1 (es) | Nuevos derivados imidazopiridina. | |
| HRP20170349T1 (hr) | Novi derivati pirola, postupak njihove priprave i farmaceutski pripravci koji ih sadrže | |
| JP2009529047A5 (https=) | ||
| EP2788000A1 (en) | Pyrrolopyrimidines as janus kinase inhibitors | |
| CN107501275A (zh) | 可用作atr激酶抑制剂的化合物 | |
| CA2636242A1 (en) | Heterobicyclic thiophene compounds and methods of use | |
| TW202140486A (zh) | 經取代１，１＇－聯苯基化合物及其使用方法 | |
| EP2403853A1 (en) | Pyrrolopyrimidines used as kinase inhibitors | |
| US8912181B2 (en) | Bicyclic compound or salt thereof | |
| CN115867541A (zh) | 氨基嘧啶酮衍生物 | |
| JP2018501315A5 (https=) | ||
| AU2009267161A1 (en) | Naphthyridininones as Aurora kinase inhibitors | |
| JP2022529061A (ja) | Ｊａｋ１選択的キナーゼ阻害剤 | |
| TW202214630A (zh) | 甲硫胺酸腺苷轉移酶抑制劑、其製備方法及應用 | |
| JPWO2021133748A5 (https=) | ||
| HRP20110332T1 (hr) | TRIAZOLO[1,5-a]KINOLINI KAO LIGANDI ADENOZINSKOG RECEPTORA A3 | |
| RU2015107426A (ru) | Пирроло[2,3-в]пиразины в качестве ингибиторов syk | |
| WO2024067660A1 (zh) | 氮杂稠环类化合物、其制备方法及其在医药上的应用 | |
| CN101005843A (zh) | 吡咯并三嗪激酶抑制剂 | |
| KR101964479B1 (ko) | 신규 푸라논 유도체 |